Latest news with #16
Irish Examiner
14 hours ago
- Sport
- Irish Examiner
Etzebeth expecting 'tight game' as Costello demands Munster discipline
It all depends where you look for the evidence that backs up Sharks captain Eben Etzebeth's prediction of 'a very close game' when Munster roll up to Kings Park on Saturday evening for this URC quarter-final. Sure, the 22-22 draw on the last day of the 2022-23 regular season will go down in the record books as a pivotal game in Munster's URC title-winning season, the second of five unbeaten matches on the road which delivered a first trophy in a dozen years to the Irish province. Yet either side of that outcome, the Sharks have enjoyed the dominance to suggest that the visitors are one lax decision or a mistimed pass away from another difficult day in Durban. That was the case three weeks before that vital share of the points. The Sharks blew Munster away on a steamy April afternoon in the Champions Cup Round of 16 with five second-half tries in a disastrous 25-minute window for the visitors, who only had their poor discipline and skill execution to blame. Yet every Munster supporter knows what their side is capable of if it all comes together and recent memories of their epic knockout victory in La Rochelle last month give hope that another famous day could be in the offing down by the Indian Ocean. A settled starting line-up certainly helps, with interim head coach Ian Costello naming an unchanged XV for third game in a row, as does the muscle memory of that title run that saw Munster visit Cape Town at the start and end of a sequence of results that also took in Durban, Glasgow and Dublin without a defeat. The 2025 Sharks, though, represent a significant challenge from two seasons ago, as their captain suggested this week as he reflected on his side coming through several close-run contests this season. 'We've seen in the past that play-offs can be tight affairs, and winning tight games is something we've done a bit of this year,' Etzebeth said. 'Last year, when we ended up lower on the log, we lost those tight games but this year we've turned things around and won them. 'We're used to those kinds of games, hopefully we don't make it that tight on Saturday. They're a quality side and it's probably going to come down to discipline on the day and who has the better goal-kicker. It's going to be a very close game.' Munster know what is coming with Costello neatly delivering a synopsis of the key threats on the squad's arrival in South Africa on Tuesday. 'We would have highlighted some areas that they are really strong – transition is the big one,' the interim head coach said. 'If you give them access through their power game, they can hurt you close to the line but if I was speaking about one area where they really come to life, it's in transition, but so do we. 'That will be a really fascinating battle. I think against Benetton, yeah we conceded two tries that we were disappointed with, but their set-piece strikes are outstanding and I probably look again at the second-half in the Ulster game and there were some outstanding defensive sets, moments, again fuelled by a lovely balance of physicality and calmness – getting that discipline balance. 'If we can keep that to the positive side, seven or eight (penalties) max, that gives us a really good chance against the Sharks. 'That's the same thing in D, having that balance of making sure that we are aggressive but also smart and disciplined with it. Costello added: 'We have had a good record here (in South Africa) and the last couple of weeks have been really good for us to deliver under pressure. It's no different this week, we need to deliver under pressure.' Sharks head coach John Plumtree's team selection on Friday underlined the size of the challenge facing Munster, with five changes from the side which edged the Scarlets 12-3 at home in the final round of the regular season a fortnight ago, and including Springbok captain Siya Kolisi and Lukhanyo Am. In contrast to an unchanged starting line-up Munster have changed up their bench from the one which came on for the final two games of the campaign to help secure bonus-point home victories over Ulster and Benetton which lifted Costello's side into the play-offs and secured Champions Cup rugby for next season. A fit-again Diarmuid Barron replaces loanee Lee Barron, an impressive try scorer off the bench against Benetton two weeks ago, as replacement hooker and there is a switch from a six-two split from the previous two outings to five forwards and three backs. Lock Fineen Wycherley is the forward to miss out while veteran scrum-half Conor Murray is joined by two fresh backline replacements in the form of Mike Haley and Rory Scannell, who is set to make his 200th appearances for Munster, as Sean O'Brien is stood down as the lone outside back cover. SHARKS: A Fassi; E Hooker, L Am, A Esterhuizen, M Mapimpi; Jordan Hendrikse, Jaden Hendrikse; O Nche, B Mbonambi, V Koch; E Etzebeth – captain, J Jenkins; J Venter, V Tshituka, S Kolisi. Replacements: F Mbatha, N Mchunu, H Jacobs, E van Heerden, P Buthelezi, B Davids, F Venter, Y Penxe MUNSTER: T Abrahams; C Nash, T Farrell, A Nankivell, D Kilgallen; J Crowley, C Casey; M Milne, N Scannell, S Archer; J Kleyn, T Beirne - captain; P O'Mahony, J Hodnett, G Coombes. Replacements: Diarmuid Barron, Josh Wycherley, John Ryan, Tom Ahern, Alex Kendellen, Conor Murray, Rory Scannell, Mike Haley. Referee: Mike Adamson (Scotland).
India Today
2 days ago
- Business
- India Today
Waiting for Form 16? Here's when will you get it and what to check
Form 16 is an important document for salaried people. It's a certificate issued by the employer, showing how much salary was paid and how much tax was deducted during the year. Many employees wait for this before filing their Income Tax Return (ITR). Wondering when it'll arrive? Here's what you need to per income tax rules, employers must file their e-TDS return for the last quarter (January–March) of the financial year by May 31. Once this is done, they have 15 days to issue Form 16. So, the last date to issue Form 16 is latest by June to CA (Dr) Suresh Surana, "Salaried employees can expect to receive Form 16 for the Financial Year 2024–25 on or before June 15, 2025, in accordance with Rule 31(1)(a) of the Income-tax Rules, 1962. Employers are mandated to issue Form 16 after filing the TDS return in Form 24Q for the fourth quarter, which is due by May 31, 2025."WHO WILL GET FORM 16? Employers are required to issue Form 16 to employees if they've deducted TDS from their salary. All salaried individuals with tax deductions are eligible to receive as per FY 2024–25 rules, no tax is payable under the new regime for income up to Rs 7 lakh, and under the old regime for income up to Rs5 lakh. So, if your salary is below these limits and no TDS was deducted, the employer may not issue Form INSIDE FORM 16?advertisementWhen it comes to filing your ITR, Form 16 plays a key role. CA Surana said, "Form 16 is a certificate of tax deducted at source (TDS) on salary and serves as a key document for filing income tax returns. It provides a detailed summary of salary paid and TDS deducted, enabling employees to accurately file their Income Tax Return (ITR) for Assessment Year 2025–26, the extended due date for which is 15 September 2025 (Circular No. 6 of 2025 dated 27 May 2025)."Form 16 consists of two parts. Part A shows quarterly details of salary paid and TDS deducted by the employer. It also includes the PAN and TAN of the employer, your PAN, and other related B gives a breakdown of your salary, exemptions, and deductions based on the investment declaration you shared and proofs you submitted. It also shows the final taxable income after considering all eligible deductions and FORM 16 PASSWORD PROTECTED?Form 16 is usually sent as a password-protected file. The password is often a combination of your PAN in either lowercase or uppercase and your date of birth in the format DDMMYYYY or DD/MM/YYYY. Your employer will usually let you know the exact format to use when they send you the in all, Form 16 is an essential piece in your tax puzzle. If your employer deducted TDS, you should get it by 15 June. Make sure all the information in it matches your Watch
Hindustan Times
3 days ago
- Hindustan Times
Three sisters drown while bathing in river Rapti, bodies recovered
: The bodies of three young girls who drowned while bathing in the Rapti River were recovered on Wednesday afternoon by the State Disaster Response Force (SDRF) and local police. The drowning took place on Tuesday evening in Mirhiriya village, under the Campierganj police station area of Gorakhpur district. The victims have been identified as Arfeen,16, and Sabreen ,14, who were sisters, and their cousin Naziya,12,. All three were residents of the same village. According to officials, four girls two sisters and their two cousins had gone to the riverbed to collect clay for plastering the walls of their house ahead of the Bakrid festival. After collecting the clay, they decided to take a bath in the river. However, they ventured too deep into the water, leading to the tragic drowning. Circle officer Gaurav Kumar Tripathi stated that recent moderate rainfall had increased the river's current, contributing to the incident. One of the girls, Sakeena ,25, cousin of the deceased Naziya, was rescued by villagers after she cried for help. Local fishermen who heard her screams rushed to the scene, but by the time they arrived, it was too late to save the other three. The SDRF divers launched an intensive search operation and successfully recovered all three bodies.
Business Wire
22-05-2025
- Business
- Business Wire
Ventus Therapeutics to Present Phase 1 Results for VENT-03, a First-in-Class cGAS Inhibitor, at LUPUS 2025
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)-- Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological, inflammatory, and neurological disorders, today announced the upcoming presentation of the Phase 1 safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) results of VENT-03 at the 16 th International Congress on Systemic Lupus Erythematosus (LUPUS 2025), taking place from May 21-24 in Toronto, Canada. VENT-03 is the first oral small-molecule cyclic GMP-AMP synthase (cGAS) inhibitor to successfully complete a first-in-human Phase 1 study and was discovered using Ventus' proprietary ReSOLVE ® platform. Data from the Phase 1 study, initially announced in October 2024, showed that VENT-03 was safe and well tolerated at all tested dose levels with a favorable PK profile enabling once-daily dosing. 'We are pleased to present at LUPUS 2025 the first reported Phase 1 results for a cGAS inhibitor, demonstrating that VENT-03 has the potential to become a first- and best-in-class therapy for lupus and other autoimmune disorders,' said Marcelo Bigal, M.D., Ph.D., President and CEO of Ventus. 'Ventus is eager to unlock the potential of cGAS inhibition across multiple autoimmune diseases, with the first Phase 2 trial evaluating VENT-03 in patients with lupus to commence later this year.' The Phase 1, double-blind, placebo-controlled, first-in-human trial included 72 healthy adult volunteers across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. The study results show that VENT-03 was safe and well tolerated up to single doses of 2000 mg once daily (QD) and multiple dosing of 900 mg QD for 10 days, which are substantially higher than our anticipated Phase 2 dose. The proportion of participants with adverse events (AEs) in the MAD cohorts was similar for VENT-03 and placebo (79% vs. 75%), and the vast majority of AEs in the study were mild and considered unrelated to the study drug. The PK profile of VENT-03 supports once-daily dosing with or without food, and the PD results demonstrate robust target engagement, supporting further clinical development. 'More than five million people worldwide are estimated to have a form of lupus. These patients can experience disease progression and severe symptoms that can affect quality of life, and currently available treatment options may not be able to adequately address these symptoms for all patients,' said Mona Kotecha, M.D., Chief Medical Officer of Ventus. 'Through targeting cGAS, VENT-03 has the potential to become a safer and more effective treatment option for patients in need, addressing key unmet needs across multiple organ systems while providing the additional benefit of once-daily oral dosing. We look forward to sharing these results and to connecting with the wider lupus community at LUPUS 2025.' Details of the poster presentation are as follows: Title: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers of VENT-03, a Novel cGAS Inhibitor for the Treatment of Systemic Lupus Erythematosus Authors: Xavier Valencia, Kelly Pike, Loraine Warner, Conrad Winters, Jeanne Stewart, Ramsay Beveridge, Patrick Cyr, Nadine Fradet, Amandine Chefson, Ofer Spiegelstein Abstract Number: Poster 286 Session Date: May 22 nd About cGAS cGAS is an intracellular pattern recognition receptor that is activated after binding to double-stranded DNA (dsDNA) in the cytoplasm. The presence of dsDNA in the cytoplasm is often the result of cellular dysfunction, which is a hallmark of many autoimmune and inflammatory diseases. Activation of cGAS leads to cGAMP formation, activation of STING, pronounced inflammation, and tissue damage. In both patients and preclinical models of disease, the cGAS pathway has been shown to be a key driver of lupus and other inflammatory diseases, such as rheumatoid arthritis, systemic sclerosis, dermatomyositis, and Sjögren's disease. About Ventus Therapeutics Ventus Therapeutics is a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological, inflammatory, and neurological disorders. Using its proprietary drug discovery platform, ReSOLVE ®, the company has established a robust pipeline, including two wholly-owned programs. VENT-03 is a first-in-class, oral cGAS inhibitor expected to enter Phase 2 development for lupus in 2025. VENT-02 is a best-in-class, brain-penetrant, oral NLRP3 inhibitor in Phase 2 for Parkinson's disease, and is expected to enter Phase 2 development for osteoarthritis in obese patients later in 2025. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted, oral NLRP3 inhibitor in Phase 1, to Novo Nordisk A/S. For more information, please visit and engage with Ventus on LinkedIn.
USA Today
21-05-2025
- Sport
- USA Today
Final vote on 'Tush Push' matched the 22-10 score in Eagles wildcard win over Packers
Final vote on 'Tush Push' matched the 22-10 score in Eagles wildcard win over Packers The Tush Push ban failed with a 22-10 vote, matching the final score in the Eagles' wild-card win over the Packers in January Karma comes in many forms, and nothing quite soothes the soul like a double-whammy of reminders for the losing team. Green Bay proposed banning the Eagles''' short-yardage 'Tush Push' play. After some very intense moments, including a plea from the legend, Jason Kelce, NFL owners met in private and came away with a 22-10 vote, keeping the play alive. The Packers needed 24 of the 32 teams to vote yes on the ban to salvage their proposal. Making it even more stinging, the final vote matched the final score from Philadelphia's 22-10 win over Green Bay in the NFC Wild Card game in January. In that win, Jalen Hurts threw two touchdown passes in his first game since a Week 16 concussion, and Dallas Goedert had the play of the game as the Philadelphia Eagles earned a 22-10 wild-card playoff win over the Green Bay Packers on Sunday night on the backs of a dynamic and playmaking defense. A.J. Brown had one catch on the night but was at peace with the outcome, and his sideline reading is a significant reason. While on the sidelines after an offensive series, Brown was spotted reading through the pages of 'Inner Excellence' by Jim Murphy. After the game, Brown explained that the book brings him inner peace.
